GlassScriptPhysician profile
Ildefonso Cruz
NPI 1275689085
$1,805.06
in general payments reported to CMS, 2019-2025
21 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $80.49 · 2021: $144 · 2022: $269 · 2023: $308 · 2024: $631 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $444.52 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $344.61 | 2020-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $164.06 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $120.79 | 2020-2023 | Repatha, Otezla |
| Pfizer INC. | $103.08 | 2019-2025 | |
| Abbvie INC. | $101.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.88 | 2022-2024 | Jardiance |
| Collegium Pharmaceutical, INC. | $57.92 | 2019 | |
| Medtronic, INC. | $50.25 | 2023 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $49.10 | 2020-2021 | |
| Esperion Therapeutics, INC. | $48.61 | 2024-2025 | Nexletol |
| Amarin Pharma, INC. | $44.20 | 2019-2020 | |
| Nevro Corp. | $33.87 | 2022 | |
| Inspire Medical Systems, INC. | $32.13 | 2024 | Inspire |
| Vertex Pharmaceuticals Incorporated | $24.63 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.13 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.88 | 2025 | Nuzyra |
| Abbott Laboratories | $17.23 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.88 | 2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ildefonso Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.